Leadership Team
Dr Ronald Shnier
Non-Executive Chairman
Dr Ronald Shnier completed a radiology fellowship at Royal Prince Alfred Hospital (RPAH) before undertaking his neuroradiology fellowship at RPAH in 1989 and musculoskeletal fellowship at the University of California Los Angeles (UCLA) in 1991. He was a consultant specialist at RPAH between 1990 and 1993. Dr Shnier started one of Australia’s first Private MRI practices in 1991 before becoming General Manager of Mayne’s Diagnostic Imaging in 2007 and was its National Director for many years. He has served on several international MRI advisory boards. Dr Shnier has a strong involvement in clinical research, and has lectured both in Australia and overseas.
Mr Maurie Stang
Non-Executive Deputy Chairman
Mr Maurie Stang has more than three decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His strong business development and marketing skills have resulted in the successful commercialisation of intellectual property across global markets. Mr Stang has been the Executive Chairman of unlisted company Lumitron Technologies since 2016.
Ms Linda Walters
Non-Executive Director
Ms Linda Walters (BEc Hon MAICD) has a strong operational, commercial and technical background across a number of life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years. Ms Walters has made a significant contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company’s technologies, intellectual property (IP) and commercialisation programme. Her expertise spans the fields of human resources, finance, information technology and the commercialisation of IP. Ms Walters has served with Regional Health Care Group and Henry Schein in a number of senior leadership roles, and was instrumental in developing Vectus’ operational and commercial capabilities.
Dr Tara Speranza
Chief Executive Officer and Chief Technology Officer
Dr Tara Speranza brings over two decades of experience spanning scientific research, commercial strategy and capital markets within the healthcare and biotechnology sectors.
Dr Speranza has over a decade of experience in academia, holding senior research positions at the University of Sydney and the University of Geneva, where her research focused on novel molecular targets and translational drug development. During this time, she led a successful commercial partnership with global pharmaceutical company, Servier, resulting in the development and commercialisation of the anti-osteoporotic therapy, Protelos.
Following her academic career, Dr Speranza has held roles across investment, strategic advisory and capital markets, supporting biotechnology and healthcare companies in valuation, capital raising, and strategic positioning. She has been directly involved in assessing and progressing investments and partnerships across a range of early- and late-stage healthcare assets, including licensing and transaction processes.
Mr Robert Waring
Company Secretary
Mr Robert Waring (BEc, CA, FCIS, FFin, FAICD) has over 50 years of experience in financial and corporate roles, including over 30 years in Company Secretarial roles for ASX-listed companies, and over 20 years as a Director of ASX-listed companies. Mr Waring has significant company secretarial experience for both listed and unlisted companies, and is currently serving as Company Secretary for ASX-listed companies Aeris Environmental Ltd and Xref Limited. He is a Director of Oakhill Hamilton Pty Ltd, which provides secretarial and corporate advisory services to a range of listed and unlisted companies.
